lonafarnib has been researched along with Cancer of Ovary in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aminossadati, B; Bachmann, HS; Burges, A; du Bois, A; Hillemanns, P; Huober, J; Kimmig, R; Kuhlmann, JD; Meier, W; Schmalfeldt, B; Sehouli, J; Siffert, W; Wimberger, P; Wollschlaeger, K | 1 |
Baumann, K; Belau, A; Burges, A; Canzler, U; du Bois, A; Gropp-Meier, M; Huober, J; Kreienberg, R; Meier, W; Rau, J; Richter, B; Schmalfeldt, B; Schröder, W; Sehouli, J; Stähle, A; Wimberger, P; Wollschlaeger, K | 1 |
Bishop, WR; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Nale, L; Taylor, SA | 1 |
Bishop, WR; Chen, J; Ferrari, E; Gurnani, M; Hajian, G; Lipari, P; Liu, M; Malkowski, M; Nielsen, LL; Shi, B; Yaremko, B | 1 |
2 trial(s) available for lonafarnib and Cancer of Ovary
Article | Year |
---|---|
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carboplatin; Farnesyltranstransferase; Female; Genetic Markers; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Piperidines; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Subunits; Pyridines; Treatment Outcome; Young Adult | 2015 |
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Prospective Studies; Pyridines; Survival Analysis; Young Adult | 2012 |
2 other study(ies) available for lonafarnib and Cancer of Ovary
Article | Year |
---|---|
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Female; HSP40 Heat-Shock Proteins; Humans; Leukocytes, Mononuclear; Mice; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Piperidines; Pyridines; Xenograft Model Antitumor Assays | 2008 |
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Topics: Adenocarcinoma; Adenoviruses, Human; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Drug Synergism; Female; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Pyridines; Teratocarcinoma; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |